📈 Revenue History (8 Quarters)
🧮 ITRMF Revenue Breakdown
Understanding Revenue
Revenue, also called sales or the "top line," represents the total income a company generates from its business activities before any costs are deducted. For ITRMF, the trailing twelve month revenue is N/A.
Why Revenue Matters
Revenue is the foundation of all financial analysis. A company cannot have sustainable profits without revenue, and revenue growth often drives stock price appreciation. However, revenue alone doesn't tell the full story - it must be analyzed alongside profitability metrics.
ITRMF's revenue growth rate of 16.12% (based on log-linear regression of 8 quarters) indicates healthy growth above the market average.
Revenue vs Profitability Metrics
Free Cash Flow: $-26.8M →
The cash remaining after capital expenditures. High revenue with negative FCF may indicate heavy reinvestment or poor cash conversion.
Owner Earnings: N/A →
Buffett's metric for true cash generation. Compares revenue's conversion to actual owner value.
Earnings Per Share: $-0.70 →
Net income per share. The bottom line result of all revenue after costs, taxes, and interest.
Net Income: $-27.0M
What remains after all expenses. Net margin shows what percentage of revenue becomes profit.
Price/Sales Ratio Analysis
ITRMF's P/S ratio of N/A means investors pay $N/A for every $1 of annual revenue.
Gross Margin: Revenue Quality
Gross margin of N/A shows how much of ITRMF's revenue remains after direct costs.
Summary: ITRMF Revenue Trend
A reliable trailing-twelve-month revenue figure for Iterum Therapeutics plc (ITRMF) is not available from its recent SEC filings, so Zyberno does not publish one. This page is excluded from search indexing until the data is available. For complete financial analysis, view the full ITRMF stock report on Zyberno.
Frequently Asked Questions
What is ITRMF's current revenue?
Iterum Therapeutics plc's trailing twelve month (TTM) revenue is N/A, growing at 16.12% annually — above the 10% threshold Zyberno considers healthy growth above market averages.
Is ITRMF's revenue growing?
A reliable trailing-twelve-month revenue figure for Iterum Therapeutics plc (ITRMF) is not available from its recent SEC filings, so Zyberno does not publish one. This page is excluded from search indexing until the data is available.
What is ITRMF's gross margin?
ITRMF's gross margin is N/A.
What is ITRMF's Price/Sales ratio?
ITRMF's P/S ratio is N/A, meaning the market values the company at N/A times its annual revenue.
How does revenue differ from profit?
Revenue is the total income before any expenses, while profit (net income) is what remains after all costs. ITRMF's revenue is N/A with a net income of $-27.0M, showing a net profit margin of N/A%.
📊 Full ITRMF Stock Report →
See ITRMF's intrinsic value, margin of safety, DCF valuation, and complete financial analysis with 250+ metrics.
💵 ITRMF Free Cash Flow →
Compare to Free Cash Flow which subtracts all capital expenditures, not just maintenance CapEx.
💰 ITRMF Owner Earnings →
Compare to Buffett's Owner Earnings metric which uses maintenance CapEx instead of total capital expenditures.
📈 ITRMF Earnings Per Share →
Analyze EPS trends, P/E ratio, earnings yield, and per-share profitability metrics.
🎯 ITRMF Earnings Surprise (SUE) →
See whether ITRMF is beating or missing its own earnings trend — Standardized Unexpected Earnings and post-earnings drift.
📊 ITRMF Revenue →
Analyze revenue trends, growth rate, P/S ratio, and top-line sales performance.
💰 ITRMF Net Income →
Analyze the bottom-line profit, P/E ratio, and net profit margin trends.
🔶 ITRMF Operating Income →
Analyze EBIT, operating margin, and core business profitability before interest and taxes.
💜 ITRMF Gross Profit →
Analyze gross margin, pricing power, and profitability before operating expenses.